Drug Research

CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

February 21, 2017

MENLO PARK, Calif.–(BUSINESS WIRE)–CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it has completed a study to evaluate the potential efficacy of its lead drug candidates, MOTS-c peptide analogs CB4209 and CB4211, in a well-established preclinical model […]

Nicox announces the presentation of NCX 667 scientific data at AOPT 2017

February 21, 2017

February 21, 2017 Sophia Antipolis, France     Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that preclinical results from its novel nitric oxide (NO) donating compound, NCX 667, were presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from February 16-19, 2017, in Florence, […]

Organovo Publishes Data Describing Physiology of 3D Bioprinted Human Kidney Tissues for Drug Toxicity Testing

February 21, 2017

SAN DIEGO, Feb. 21, 2017 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced the publication of data in Frontiers in Physiology showing the company’s 3D bioprinted proximal tubule tissue model exhibits key characteristics of renal physiology that […]

Corbus Pharmaceuticals to Host Research and Development Day on March 13, 2017

February 21, 2017

NORWOOD, MA–(Marketwired – February 21, 2017) – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced that it will host its inaugural Research and Development (R&D) Day event for the institutional investment community in New York City on […]

Taconic Biosciences Generates Vici Syndrome Mouse Model

February 20, 2017

HUDSON, NY–(Marketwired – Feb 17, 2017) – Taconic Biosciences, a global leader in genetically engineered rodent models and associated services, announced it has generated a novel mouse model of Vici syndrome for use by two investigators studying this rare disease. As a corporate sponsor of the Rare Disease Science Challenge: BeHEARD, hosted by the Rare […]

ORYZON to present ORY-2001 new preclinical data of therapeutic activity at ACTRIMS-2017 in Orlando, Fl. USA

February 20, 2017

BARCELONA, SPAIN and CAMBRIDGE, MA–(Marketwired – February 20, 2017) – Oryzon Genomics (ISIN Code: ES0167733015) (MAD: ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will present new preclinical data of therapeutic activity in Multiple Sclerosis of ORY-2001, a novel epigenetic drug […]

Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD

February 17, 2017

LA JOLLA, Calif., Feb. 16, 2017 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Nature Communications has published an article entitled “microRNA-17 family promotes polycystic kidney disease progression through the modulation of mitochondrial metabolism.” The article highlights research that identifies […]

Champions Oncology Announces New Collection of Patient-Derived Xenograft (PDX) Models Available for Translational Research

February 17, 2017

HACKENSACK, N.J., Feb. 16, 2017 /PRNewswire/ — Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the addition of new cohorts of PDX models to their existing TumorBank.   These new models will expand […]

Capricor Therapeutics Provides Update on Natriuretic Peptide Program

February 17, 2017

LOS ANGELES, Feb. 16, 2017 /PRNewswire/ — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and other medical conditions, today announced that it has elected to terminate its license agreement with the Mayo Clinic relating to natriuretic peptide receptor agonists, including Cenderitide.   “Our decision to return these […]

Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial

February 16, 2017

Merck dropped a Valentine’s Day downer announcing they will stop the EPOCH trial of verubecestat in mild to moderate Alzheimer’s disease. A prespecified interim analysis by an external data-monitoring committee gave the trial “virtually no chance of finding a positive effect,” according to a Merck press release. The trial had been slated to run until […]

Windtree Therapeutics’ Aerosolized KL4 Surfactant Reduces Lung Inflammation and Improves Survival in a High-Pathogen Avian Influenza Preclinical Study

February 16, 2017

WARRINGTON, Pa., Feb. 16, 2017 /PRNewswire/ — Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focusing on developing aerosolized KL4 surfactant therapies for respiratory diseases, announced today that data from a preclinical influenza study showed that aerosolized KL4 surfactant reduced lung inflammation and improved overall survival in a well-established preclinical animal model. The Company believes […]

ERT Recognized for Improving and Accelerating Clinical Research

February 16, 2017

ERT Recognized for Improving and Accelerating Clinical Research Company Named Finalist for PACT Technology Company of the Year Award PHILADELPHIA – Feb 16, 2017–– ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, today announced it has been named a finalist for the Philadelphia Alliance for Capital and Technologies […]

Selecta Biosciences Announces Preclinical Data Showing SVP-Rapamycin’s Potential Benefit in Treatment of Pompe Disease

February 15, 2017

WATERTOWN, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious diseases that avoid unwanted immunogenicity, today announced that results from preclinical studies involving the use of SVP-Rapamycin in combination with alglucosidase alfa (marketed as Myozyme® and Lumizyme®) to treat Pompe […]

Certara Vice President Appointed F1000Prime Faculty Member

February 15, 2017

F1000Prime is a global organization of leading scientists and clinicians that evaluates important biology and medical research papers Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced that Professor Piet van der Graaf, PharmD, PhD, its vice president of quantitative systems pharmacology, has […]

Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease

February 14, 2017

CALGARY, Feb. 13, 2017 /PRNewswire/ – Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today highlighted two potentially new indications recently identified by third party academic research involving its lead drug, apabetalone. The first indication was published in the Journal of Neuroinflammation which described the inhibition of bromodomain and extra-terminal (BET) epigenetic readers, including apabetalone […]

marcus evans organize the 4th Edition IDMP Compliance Challenge: Navigating through uncertainty Conference

February 14, 2017

This marcus evans conference will focus on IDMP compliance preparations benchmarking and knowledge-sharing for the phased approach deadlines in the context uncertainty and expectations for the final guidelines. Despite the fact the implementation guidelines have not been published yet, decisions about the compliance preparations need to be already made today as this legislation has major […]

Mateon Therapeutics Announces Initial Pre-clinical Data on Combination of CA4P with Checkpoint Inhibitors

February 14, 2017

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced encouraging preliminary data from four different syngeneic mouse models evaluating Mateon’s lead investigational drug CA4P in combination with checkpoint inhibitors. The most compelling results […]

Mateon Therapeutics Announces Initial Pre-Clinical Data on Combination of CA4P With Checkpoint Inhibitors

February 14, 2017

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced encouraging preliminary data from four different syngeneic mouse models evaluating Mateon’s lead investigational drug CA4P in combination with checkpoint inhibitors. The most compelling results […]

Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors

February 14, 2017

SEATTLE–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ:GILD) today announced findings from a preclinical study evaluating HIV capsid inhibitors (CAIs) for potential use as a long-acting antiretroviral (ARV) treatment. The study identified novel HIV-1 capsid inhibitors with highly potent antiviral activity and a favorable resistance profile to existing ARVs in vitro. The data are being presented in an […]

Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model

February 14, 2017

RADNOR, Pa., Feb. 14, 2017 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the publication of preclinical data in the January issue of Neuropharmacology, showing that its positive allosteric modulator of GABAA, ganaxolone ameliorates many of the behavioral […]

New Webinar Introduces DrugDev Spark™, First Unified Clinical Operations Suite, with Proven Solutions Including Site Selection, Activation, Payments, Engagement, eConsent

February 14, 2017

Find out how 85 sponsors and CROs of all sizes are disrupting trials with an innovative platform used on over 1,800 clinical trials worldwide – all tied together with the award-winning DrugDev Golden Number data standard King of Prussia, PA – DrugDev Spark™ changes the dynamic of the industry’s technology landscape by providing the first […]

Mount Tam Biotechnologies Announces TAM-03, a Novel Compound with Potential to Treat a Range of Cancer Types

February 13, 2017

NOVATO, CA–(Marketwired – Feb 13, 2017) – Mount Tam Biotechnologies, Inc. (“Mount Tam”) (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, announces that it will advance a novel ‘rapalog’, TAM-03, for further development efforts with the ultimate goal of moving TAM-03 into the clinic to treat certain advanced […]

Syros Announces Publication in Cell Highlighting Gene Control as Important and Rapidly Progressing Area of Research for Yielding New Medicines to Treat Cancer

February 10, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS) today announced the publication of a paper in a special cancer-focused issue of the scientific journal Cell that highlights gene control as an important area for cancer drug discovery and development, underscoring the promise of Syros’ pioneering approach to advance a new wave of medicines that control the expression of […]

Selcia, Cypralis and Gilead publish synthetic macrocyclic cyclophilin inhibitors inspired by natural product sanglifehrin A

February 10, 2017

Ongar, UK, 10th February 2017 / Sciad Newswire / Selcia, with colleagues from Cypralis and Gilead Sciences Inc., have published in the Journal of Medicinal Chemistry a novel strategy of structural simplification of a natural product to generate synthetically tractable cyclophilin inhibitors for the treatment of HCV. Cyclophilin inhibitors on the market or in clinical […]

Gene for a New Form of Muscular Dystrophy Found by Researchers Funded by March of Dimes

February 10, 2017

WHITE PLAINS, N.Y., Feb. 9, 2017 /PRNewswire-USNewswire/ — A medical mystery for children with an unusual array of symptoms has been unlocked by researchers funded in part by the March of Dimes, who have identified a genetic mutation underlying a new form of muscular dystrophy (MD). The work was published today in the American Journal […]

iX Biopharma 2Q17 Update on Drug Development

February 9, 2017

NEWS RELEASE 2Q17 UPDATE ON DRUG DEVELOPMENT Singapore, 8 February 2017 – For the financial quarter ended 31 December 2016 (“2Q17”), specialty pharmaceutical company iX Biopharma Ltd (“iX Biopharma” or, together with its subsidiaries, “the Group”) continued its preparations for the registration of two products with the Therapeutic Goods Administration (“TGA”) in Australia, and for […]

ERT’s eCOA Environment Accelerates Research Without Technology Getting in the Way

February 9, 2017

ERT’s eCOA Environment Accelerates Research Without Technology Getting in the Way Enhanced technology environment simplifies implementation and utilization to make electronic Clinical Outcome Assessments (eCOA) accessible for every trial PHILADELPHIA – Feb 9, 2017–– ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, today announced the launch of its […]

Spotlight Innovation Engages Top-Tier Contract Research Organization to Conduct Preclinical Studies of STL-182

February 8, 2017

URBANDALE, Iowa, Feb. 8, 2017 /PRNewswire/ — Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that it has engaged a top-tier contract research organization (CRO) to conduct additional preclinical mouse studies of STL-182, the Company’s proprietary small molecule product candidate for the treatment of spinal muscular atrophy […]

FEEDBACK